Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

2.

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.

Sluis-Cremer N, Jordan MR, Huber K, Wallis CL, Bertagnolio S, Mellors JW, Parkin NT, Harrigan PR.

Antiviral Res. 2014 Jul;107:31-4. doi: 10.1016/j.antiviral.2014.04.001. Epub 2014 Apr 16.

3.

Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir.

Young TP, Napolitano LA, Paquet AC, Parkin NT, Fransen S, Trinh R, Haddad M, Hackett J Jr, Cloherty GA.

J Virol Methods. 2013 Nov;193(2):693-6. doi: 10.1016/j.jviromet.2013.07.028. Epub 2013 Jul 25.

PMID:
23892128
4.

Sequence conservation of the region targeted by the Abbott RealTime HBV viral load assay in clinical specimens.

Cloherty GA, Rhoads J, Young TP, Parkin NT, Holzmayer V, Yuen L, Mullen C.

J Clin Microbiol. 2013 Apr;51(4):1260-2. doi: 10.1128/JCM.03003-12. Epub 2013 Jan 23.

5.

Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.

Acosta EP, Limoli KL, Trinh L, Parkin NT, King JR, Weidler JM, Ofotokun I, Petropoulos CJ.

Antimicrob Agents Chemother. 2012 Nov;56(11):5938-45. doi: 10.1128/AAC.00691-12. Epub 2012 Sep 10.

6.

Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations.

Young TP, Cloherty G, Fransen S, Napolitano L, Swanson P, Herman C, Parkin NT, Hackett J Jr.

J Clin Microbiol. 2011 Apr;49(4):1631-4. doi: 10.1128/JCM.02253-10. Epub 2011 Feb 2.

7.

Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance.

Bertagnolio S, Parkin NT, Jordan M, Brooks J, García-Lerma JG.

AIDS Rev. 2010 Oct-Dec;12(4):195-208. Review.

PMID:
21179184
8.

Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.

Young TP, Parkin NT, Stawiski E, Pilot-Matias T, Trinh R, Kempf DJ, Norton M.

Antimicrob Agents Chemother. 2010 Nov;54(11):4903-6. doi: 10.1128/AAC.00906-10. Epub 2010 Aug 30.

9.

In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.

Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR.

J Virol. 2009 Feb;83(4):2038-43. doi: 10.1128/JVI.02154-08. Epub 2008 Nov 19.

10.
11.

Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman DD.

J Virol. 2008 Jun;82(11):5510-8. doi: 10.1128/JVI.02579-07. Epub 2008 Mar 19.

12.

Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

Cihlar T, Ray AS, Boojamra CG, Zhang L, Hui H, Laflamme G, Vela JE, Grant D, Chen J, Myrick F, White KL, Gao Y, Lin KY, Douglas JL, Parkin NT, Carey A, Pakdaman R, Mackman RL.

Antimicrob Agents Chemother. 2008 Feb;52(2):655-65. Epub 2007 Dec 3.

13.

Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.

Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin NT, Petropoulos CJ.

J Virol. 2007 Aug;81(15):7885-93. Epub 2007 May 16.

14.

Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.

Villena C, Prado JG, Puertas MC, Martínez MA, Clotet B, Ruiz L, Parkin NT, Menéndez-Arias L, Martinez-Picado J.

J Virol. 2007 May;81(9):4713-21. Epub 2007 Feb 21.

15.

Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase.

Berkhout B, Back NK, de Ronde A, Jurriaans S, Bakker M, Parkin NT, van der Hoek L.

AIDS. 2006 Jul 13;20(11):1515-20.

PMID:
16847406
16.
17.
18.

HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.

Prado JG, Parkin NT, Clotet B, Ruiz L, Martinez-Picado J.

Clin Infect Dis. 2005 Sep 1;41(5):729-37. Epub 2005 Jul 22.

PMID:
16080097
19.

Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.

Martinez-Picado J, Wrin T, Frost SD, Clotet B, Ruiz L, Brown AJ, Petropoulos CJ, Parkin NT.

J Virol. 2005 May;79(10):5907-13.

20.

Evidence for positive epistasis in HIV-1.

Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ.

Science. 2004 Nov 26;306(5701):1547-50. Erratum in: Science. 2008 May 9;320(5877):746.

21.

Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.

Grossman Z, Paxinos EE, Averbuch D, Maayan S, Parkin NT, Engelhard D, Lorber M, Istomin V, Shaked Y, Mendelson E, Ram D, Petropoulos CJ, Schapiro JM.

Antimicrob Agents Chemother. 2004 Jun;48(6):2159-65.

22.

Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV.

Parkin NT, Schapiro JM.

Antivir Ther. 2004 Feb;9(1):3-12. Review.

PMID:
15040531
23.

Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ.

Antimicrob Agents Chemother. 2004 Feb;48(2):437-43.

24.

Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.

Lam E, Parkin NT.

Clin Infect Dis. 2003 Nov 1;37(9):1273-4. No abstract available.

PMID:
14557976
25.

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.

Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, Selmi B, Boretto J, Canard B.

J Biol Chem. 2004 Jan 2;279(1):509-16. Epub 2003 Oct 9.

26.

Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ.

J Infect Dis. 2003 Oct 1;188(7):992-1000. Epub 2003 Sep 16.

PMID:
14513419
27.
28.

New ways of initiating translation in eukaryotes.

Schneider R, Agol VI, Andino R, Bayard F, Cavener DR, Chappell SA, Chen JJ, Darlix JL, Dasgupta A, Donzé O, Duncan R, Elroy-Stein O, Farabaugh PJ, Filipowicz W, Gale M Jr, Gehrke L, Goldman E, Groner Y, Harford JB, Hatzglou M, He B, Hellen CU, Hentze MW, Hershey J, Hershey P, Hohn T, Holcik M, Hunter CP, Igarashi K, Jackson R, Jagus R, Jefferson LS, Joshi B, Kaempfer R, Katze M, Kaufman RJ, Kiledjian M, Kimball SR, Kimchi A, Kirkegaard K, Koromilas AE, Krug RM, Kruys V, Lamphear BJ, Lemon S, Lloyd RE, Maquat LE, Martinez-Salas E, Mathews MB, Mauro VP, Miyamoto S, Mohr I, Morris DR, Moss EG, Nakashima N, Palmenberg A, Parkin NT, Pe'ery T, Pelletier J, Peltz S, Pestova TV, Pilipenko EV, Prats AC, Racaniello V, Read GS, Rhoads RE, Richter JD, Rivera-Pomar R, Rouault T, Sachs A, Sarnow P, Scheper GC, Schiff L, Schoenberg DR, Semler BL, Siddiqui A, Skern T, Sonenberg N, Sossin W, Standart N, Tahara SM, Thomas AA, Toulmé JJ, Wilusz J, Wimmer E, Witherell G, Wormington M.

Mol Cell Biol. 2001 Dec;21(23):8238-46. No abstract available.

29.

Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.

Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, Fiscus SA.

J Infect Dis. 2001 Jun 1;183(11):1688-93. Epub 2001 Apr 23.

PMID:
11343221
30.

A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.

Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ, Parkin NT.

J Virol. 2000 May;74(9):4414-9.

31.

Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients.

Parkin NT, Deeks SG, Wrin MT, Yap J, Grant RM, Lee KH, Heeren D, Hellmanna NS, Petropoulos CJ.

AIDS. 2000 Dec 22;14(18):2877-87.

PMID:
11153669
32.

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM.

Antimicrob Agents Chemother. 2000 Apr;44(4):920-8.

33.

Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.

Parkin NT, Lie YS, Hellmann N, Markowitz M, Bonhoeffer S, Ho DD, Petropoulos CJ.

J Infect Dis. 1999 Sep;180(3):865-70.

PMID:
10438382
34.
35.

Genetically engineered live attenuated influenza A virus vaccine candidates.

Parkin NT, Chiu P, Coelingh K.

J Virol. 1997 Apr;71(4):2772-8.

36.
37.

Activity of Wnt-1 as a transmembrane protein.

Parkin NT, Kitajewski J, Varmus HE.

Genes Dev. 1993 Nov;7(11):2181-93.

39.

Control of the interferon-induced 68-kilodalton protein kinase by the HIV-1 tat gene product.

Roy S, Katze MG, Parkin NT, Edery I, Hovanessian AG, Sonenberg N.

Science. 1990 Mar 9;247(4947):1216-9.

PMID:
2180064
41.
42.

Supplemental Content

Loading ...
Support Center